242 related articles for article (PubMed ID: 30992185)
1. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing.
Ning MS; Klopp AH; Jhingran A; Lin LL; Eifel PJ; Vedam S; Lawyer AA; Olivieri ND; Guzman AB; Incalcaterra JR; Mesko SM; Pezzi TA; Boyce-Fappiano DR; Shaitelman SF; Frank SJ; Thaker NG
Brachytherapy; 2019; 18(4):445-452. PubMed ID: 30992185
[TBL] [Abstract][Full Text] [Related]
2. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Delivery Costs for External Beam Radiation Therapy and Brachytherapy for Locally Advanced Cervical Cancer Using Time-Driven Activity-Based Costing.
Bauer-Nilsen K; Hill C; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):88-94. PubMed ID: 29079120
[TBL] [Abstract][Full Text] [Related]
4. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.
Roberts KB; Soulos PR; Herrin J; Yu JB; Long JB; Dostaler E; Gross CP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1186-92. PubMed ID: 23182396
[TBL] [Abstract][Full Text] [Related]
5. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
6. Time-driven activity-based costing of adjuvant vaginal cuff brachytherapy for uterine cancer in an integrated brachytherapy suite.
Su L; Dutta SW; Sanders JC; Wu T; Libby B; Romano KD; Showalter TN
Brachytherapy; 2020; 19(2):176-180. PubMed ID: 31870729
[TBL] [Abstract][Full Text] [Related]
7. Time-driven activity-based costing of a novel form of CT-guided high-dose-rate brachytherapy intraoperative radiation therapy compared with conventional breast intraoperative radiation therapy for early stage breast cancer.
Suralik G; Rudra S; Dutta SW; Yu J; Sanders JC; Schad MD; Janowski EM; Su L; Libby B; Showalter SL; Lobo JM; Showalter TN
Brachytherapy; 2020; 19(3):348-354. PubMed ID: 32229072
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
Zhang Y; Rovirosa A; Ascaso C; Herreros A; Torne A; Li Y; Biete A; Sánchez J
Brachytherapy; 2020; 19(1):60-65. PubMed ID: 31587986
[TBL] [Abstract][Full Text] [Related]
10. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer.
Ilg AM; Laviana AA; Kamrava M; Veruttipong D; Steinberg M; Park SJ; Burke MA; Niedzwiecki D; Kupelian PA; Saigal C
Brachytherapy; 2016; 15(6):760-767. PubMed ID: 27720202
[TBL] [Abstract][Full Text] [Related]
11. Time-Driven, Activity-Based Cost Analysis of Radiation Treatment Options for Spinal Metastases.
Boyce-Fappiano D; Ning MS; Thaker NG; Pezzi TA; Gjyshi O; Mesko S; Anakwenze C; Olivieri ND; Guzman AB; Incalcaterra JR; Tang C; McAleer MF; Herman J; Ghia AJ
JCO Oncol Pract; 2020 Mar; 16(3):e271-e279. PubMed ID: 31765268
[TBL] [Abstract][Full Text] [Related]
12. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
13. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis.
Ning MS; Venkatesan AM; Stafford RJ; Bui TP; Carlson R; Bailard NS; Vedam S; Davis R; Olivieri ND; Guzman AB; Incalcaterra JR; McKelvey FA; Thaker NG; Rauch GM; Tang C; Frank SJ; Joyner MM; Lin LL; Jhingran A; Eifel PJ; Klopp AH
Brachytherapy; 2020; 19(4):427-437. PubMed ID: 31786169
[TBL] [Abstract][Full Text] [Related]
14. A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients.
Aydogan B; Mundt AJ; Smith BD; Mell LK; Wang S; Sutton H; Roeske JC
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):266-73. PubMed ID: 16618581
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
[TBL] [Abstract][Full Text] [Related]
16. A cost comparison analysis of adjuvant radiation therapy techniques after breast-conserving surgery.
Lanni T; Keisch M; Shah C; Wobb J; Kestin L; Vicini F
Breast J; 2013; 19(2):162-7. PubMed ID: 23294184
[TBL] [Abstract][Full Text] [Related]
17. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
18. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
[TBL] [Abstract][Full Text] [Related]
19. Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer.
Thaker NG; Boyce-Fappiano D; Ning MS; Pasalic D; Guzman A; Smith G; Holliday EB; Incalcaterra J; Garden AS; Shaitelman SF; Gunn GB; Fuller CD; Blanchard P; Feeley TW; Kaplan RS; Frank SJ
Int J Part Ther; 2021; 8(1):374-382. PubMed ID: 34285963
[TBL] [Abstract][Full Text] [Related]
20. A comparative study using time-driven activity-based costing in single-fraction breast high-dose rate brachytherapy: An integrated brachytherapy suite vs. decentralized workflow.
Squeo GC; Lattimore CM; Simone NL; Suralik G; Dutta SW; Schad MD; Su L; Libby B; Janowski EM; Showalter SL; Lobo JM; Showalter TN
Brachytherapy; 2022; 21(3):334-340. PubMed ID: 35125328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
